The Latest Cardiac and Vascular News
EDEN PRAIRIE, Minn., Jan. 31, 2019 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), today announced the initiation of a distribution agreement in the Indian market with Wayinia Lifesciences. This agreement expands the company’s sales outreach in Asia, while opening new access to one of the larger population centers in the […]
BASEL, Switzerland and DURHAM, N.C., Jan. 31, 2019 /PRNewswire/ — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute (PVRI) 13th Annual World Congress on Pulmonary Vascular Disease, […]
VANCOUVER, Jan. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the “Institut für das Entgeltsystem im Krankenhaus” (“InEk”), the […]
BEVERLY HILLS, Calif., Jan. 29, 2019 /PRNewswire/ — Without new treatment options and greater utilization of current cholesterol lowering therapies, the mortality rate from cardiovascular disease (CVD) could increase 62 percent by 2040, according to a study published in the January issue of Clinical Cardiology. While deaths due to CVD have declined over the past 50 years due to improved management […]
WINNIPEG, Jan. 28, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce it has entered into an agreement with Sensible Medical Innovations Inc. (“Sensible”) to become the exclusive marketing partner for the ReDS™ point of care system (“ReDS”) in the United States. ReDS is […]
VANCOUVER, Jan 29, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has completed the Phase 1 requirements of the […]
MONTGOMERY, Ala.–(BUSINESS WIRE)–Kowa Pharmaceuticals America, Inc. announced today that it has entered into an agreement with Allergan plc. to co-promote Allergan’s BYSTOLIC® (nebivolol), a beta blocker approved for the treatment of hypertension to lower blood pressure, in the United States. Kowa’s nationwide sales force will co-promote BYSTOLIC to cardiologists and select […]
KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., announces publication of data for two more tests, HART AS and HART AKI, in its expanding pipeline of multi-protein, AI-driven tests for cardiovascular disease and related conditions. The HART AS data was presented at the 2018 American College of Cardiology Scientific Sessions and was recently published in Open Heart, indicating […]
IRVINE, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced its objectives for its upcoming CoreoGraft® study at the Texas Heart Institute. The study will begin the week of January 28. […]
SAN DIEGO, Jan. 24, 2019 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH). The global license […]
